The Eye as a Window to the Gut: A Novel Digital Biomarker for Systemic Health
A recent study in Alzheimer’s & Dementia presents a novel eye-tracking digital marker that outperforms established plasma biomarkers in detecting cognitive impairment. The research, involving 276 participants, found that a panel of eye-tracking metrics achieved an area under the curve (AUC) of 0.865 for classifying cognitive impairment, surpassing the performance of plasma biomarkers including Aβ42/40, p-Tau217, GFAP, and NfL. This non-invasive tool demonstrates a strong correlation with traditional Alzheimer’s disease biomarkers from PET and MRI scans, offering a rapid, scalable method for cognitive screening. The findings highlight the potential of digital phenotyping to provide sensitive, accessible diagnostics for neurological conditions, which may have broader implications for monitoring systemic health and disease progression.
Study Significance: For gastroenterology and hepatology professionals, this research underscores a paradigm shift towards non-invasive, digital biomarkers for chronic disease management. The demonstrated link between ocular motility and central nervous system pathology suggests potential parallel applications in hepatology, such as using eye-tracking to detect covert hepatic encephalopathy or early neurological sequelae of cirrhosis. This approach could streamline patient stratification for complex procedures like transplant evaluation, moving beyond purely biochemical panels to integrated digital-physiological assessments.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
